Introduction: Evidence has suggested an association between bacterial infection and increased risk of subsequent major mental disorders (MMDs). Whether such association varies with different pathogens remains unclear. We aimed to investigate the risk of subsequent MMDs after exposure to bacterial pathogens in children and adolescents. Methods: Between 1997 and 2012, we enrolled a nationwide cohort of 14,024 children and adolescents with hospitalized bacterial infection, and noninfected controls were 1:4 matched for demographics. There were 11 investigated pathogens, namely, Streptococcus, Staphylococcus, Pseudomonas, Klebsiella, Hemophilus, Mycoplasma, Tuberculosis, Meningococcus, Escherichia, Chlamydia, and Scrub typhus. The primary outcomes were the subsequent risk of seven MMDs, namely, autism spectrum disorder (ASD), attention-deficiency hyperactivity disorder (ADHD), obsessive-compulsive disorder (OCD), tic disorder, schizophrenia, bipolar disorder, and depressive disorder. The secondary outcomes were the subsequent risk of exposure to psychotropic medications. Results: Pooled bacterial infection was associated with increased risk of the six MMDs – ASD (reported as hazard ratios with 95% confidence intervals: 13.80; 7.40–25.75), ADHD (6.93; 5.98–8.03), OCD (3.93; 1.76–8.76), tic disorder (6.19; 4.44–8.64), bipolar disorder (2.50; 1.28–4.86), and depressive disorder (1.93; 1.48–2.51) – and exposure to four psychotropic medications, including ADHD drugs (11.81; 9.72–14.35), antidepressants (2.96; 2.45–3.57), mood stabilizers (4.51; 2.83–7.19), and atypical antipsychotics (4.23; 3.00–5.96) compared to controls. The associations among MMDs and specific pathogens varied. Importantly, Streptococcus was associated with the most MMDs (six MMDs), and ADHD was associated with eight bacterial pathogen infections. Conclusions: After bacterial infection, the risk of MMDs increased in children and adolescents compared to controls, and such associations varied with different pathogens. Future studies are warranted to validate our study findings and investigate the potential mechanisms.

Keywords:
Bacterial infection, Attention-deficit hyperactivity disorder, Autism spectrum disorder, Streptococcus, Mycoplasma
1.
Marín O. Developmental timing and critical windows for the treatment of psychiatric disorders.
Nat Med
. 2016;22(11):1229–38.
2.
Al-Haddad BJS, Jacobsson B, Chabra S, Modzelewska D, Olson EM, Bernier R, et al. Long-term risk of neuropsychiatric disease after exposure to infection in utero.
JAMA Psychiatry
. 2019;76(6):594–602.
3.
Blomström A, Karlsson H, Gardner R, Jörgensen L, Magnusson C, Dalman C. Associations between maternal infection during pregnancy, childhood infections, and the risk of subsequent psychotic disorder: a Swedish Cohort Study of nearly 2 million individuals.
Schizophr Bull
. 2016;42(1):125–33.
4.
Köhler-Forsberg O, Petersen L, Gasse C, Mortensen PB, Dalsgaard S, Yolken RH, et al. A Nationwide Study in Denmark of the association between treated infections and the subsequent risk of treated mental disorders in children and adolescents.
JAMA Psychiatry
. 2019;76(3):271–9.
5.
Green MJ, Watkeys OJ, Whitten T, Thomas C, Kariuki M, Dean K, et al. Increased incidence of childhood mental disorders following exposure to early life infection.
Brain Behav Immun
. 2021;97:376–82.
6.
Kannan G, Gressitt KL, Yang S, Stallings CR, Katsafanas E, Schweinfurth LA, et al. Pathogen-mediated NMDA receptor autoimmunity and cellular barrier dysfunction in schizophrenia.
Transl Psychiatry
. 2017;7(8):e1186.
7.
Swedo SE, Leonard HL, Garvey M, Mittleman B, Allen AJ, Perlmutter S, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases.
Am J Psychiatry
. 1998;155(2):264–71.
8.
Banerjee B, Petersen K. Psychosis following mycoplasma pneumonia.
Mil Med
. 2009;174(9):1001–4.
9.
Kammer J, Ziesing S, Davila LA, Bültmann E, Illsinger S, Das AM, et al. Neurological manifestations of mycoplasma pneumoniae infection in hospitalized children and their long-term follow-up.
Neuropediatrics
. 2016;47(5):308–17.
10.
Piras C, Pintus R, Pruna D, Dessì A, Atzori L, Fanos V. Pediatric acute-onset neuropsychiatric syndrome and mycoplasma pneumoniae infection: a case report analysis with a metabolomics approach.
Curr Pediatr Rev
. 2020;16(3):183–93.
11.
Tsai CS, Chen VC, Yang YH, Hung TH, Lu ML, Huang KY, et al. The association between Mycoplasma pneumoniae infection and speech and language impairment: a nationwide population-based study in Taiwan.
PLoS One
. 2017;12(7):e0180402.
12.
Fu M, Wong KS, Lam WW, Wong GW. Middle cerebral artery occlusion after recent Mycoplasma pneumoniae infection.
J Neurol Sci
. 1998;157(1):113–5.
13.
Mulder LJ, Spierings EL. Stroke in a young adult with Mycoplasma pneumoniae infection complicated by intravascular coagulation.
Neurology
. 1987;37(8):1430–1.
14.
Huang JS, Yang FC, Chien WC, Yeh TC, Chung CH, Tsai CK, et al. Risk of substance use disorder and its associations with comorbidities and psychotropic agents in patients with autism.
JAMA Pediatr
. 2021;175(2):e205371.
15.
Liang CS, Bai YM, Hsu JW, Huang KL, Ko NY, Chu HT, et al. The risk of sexually transmitted infections following first-episode schizophrenia among adolescents and young adults: a Cohort Study of 220,545 subjects.
Schizophr Bull
. 2020;46(4):795–803.
16.
Chen MH, Hsu JW, Huang KL, Bai YM, Ko NY, Su TP, et al. Sexually transmitted infection among adolescents and young adults with attention-deficit/hyperactivity disorder: a Nationwide Longitudinal Study.
J Am Acad Child Adolesc Psychiatry
. 2018;57(1):48–53.
17.
Chen MH, Hsu JW, Huang KL, Su TP, Li CT, Lin WC, et al. Risk and coaggregation of major psychiatric disorders among first-degree relatives of patients with bipolar disorder: a nationwide population-based study.
Psychol Med
. 2019:49:2397–404.
18.
Chen MH, Lan WH, Hsu JW, Huang KL, Su TP, Li CT, et al. Risk of developing type 2 diabetes in adolescents and young adults with autism spectrum disorder: a Nationwide Longitudinal Study.
Diabetes Care
. 2016;39(5):788–93.
19.
Zhang B, Wang HE, Bai YM, Tsai SJ, Su TP, Chen TJ, et al. Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study.
Gut
. 2021;70(1):85–91.
20.
Kuo SC, Shih SM, Hsieh LY, Lauderdale TY, Chen YC, Hsiung CA, et al. Antibiotic restriction policy paradoxically increased private drug consumptions outside Taiwan’s National Health Insurance.
J Antimicrob Chemo-ther
. 2017;72(5):1544–5.
21.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
J Chronic Dis
. 1987;40(5):373–83.
22.
Liu CY, Hung YT, Chuang YL, Chen YJ, Weng WS, Liu JS. Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey.
J Health Management
. 2006;4:1–22.
23.
Nielsen PR, Benros ME, Mortensen PB. Hospital contacts with infection and risk of schizophrenia: a population-based cohort study with linkage of Danish national registers.
Schizophr Bull
. 2014;40(6):1526–32.
24.
Lepri G, Rigante D, Bellando Randone S, Meini A, Ferrari A, Tarantino G, et al. Clinical-serological characterization and treatment outcome of a large cohort of italian children with pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection and pediatric acute neuropsychiatric syndrome.
J Child Adolesc Psychopharmacol
. 2019;29(8):608–14.
25.
Thomas L, Aleu F, Bitensky MW, Davidson M, Gesner B. Studies of PPLO infection. II. The neurotoxin of Mycoplasma neurolyticum.
J Exp Med
. 1966;124(6):1067–82.
26.
Thomas L, Davidson M, McCluskey RT. Studies of PPLO infection. I. The production of cerebral polyarteritis by Mycoplasma gallisepticum in turkeys; the neurotoxic property of the Mycoplasma.
J Exp Med
. 1966;123(5):897–912.
27.
Müller N. Infectious diseases and mental health.
Comorbidity Ment Phys Disord
. 2014;99.
28.
Kirvan CA, Swedo SE, Snider LA, Cunningham MW. Antibody-mediated neuronal cell signaling in behavior and movement disorders.
J Neuroimmunol
. 2006;179(1–2):173–9.
29.
Moretti G, Pasquini M, Mandarelli G, Tarsitani L, Biondi M. What every psychiatrist should know about PANDAS: a review.
Clin Pract Epidemiol Ment Health
. 2008;4:13.
30.
Xu J, Liu RJ, Fahey S, Frick L, Leckman J, Vaccarino F, et al. Antibodies from children with PANDAS bind specifically to striatal cholinergic interneurons and alter their activity.
Am J Psychiatry
. 2021;178(1):48–64.
31.
Doherty AM, Kelly J, McDonald C, O’Dywer AM, Keane J, Cooney J. A review of the interplay between tuberculosis and mental health.
Gen Hosp Psychiatry
. 2013;35(4):398–406.
32.
Jackson-Cowan L, Cole EF, Arbiser JL, Silverberg JI, Lawley LP. TH2 sensitization in the skin-gut-brain axis: how early-life Th2-mediated inflammation may negatively perpetuate developmental and psychologic abnormalities.
Pediatr Dermatol
. 2021;38(5):1032–9.
33.
Nikolova VL, Hall MRB, Hall LJ, Cleare AJ, Stone JM, Young AH. Perturbations in gut microbiota composition in psychiatric disorders.
JAMA Psychiatry
. 2021;78(12):1343–54.
34.
Severance EG, Yolken RH, Eaton WW. Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling.
Schizophr Res
. 2016;176(1):23–35.
35.
Foldager L, Köhler O, Steffensen R, Thiel S, Kristensen AS, Jensenius JC, et al. Bipolar and panic disorders may be associated with hereditary defects in the innate immune system.
J Affect Disord
. 2014;164:148–54.
36.
Nadeem A, Ahmad SF, Al-Harbi NO, AL-Ayadhi LY, Sarawi W, Attia SM, et al. Imbalance in pro-inflammatory and anti-inflammatory cytokines milieu in B cells of children with autism.
Mol Immunol
. 2022;141:297–304.
37.
Tylee DS, Sun J, Hess JL, Tahir MA, Sharma E, Malik R, et al. Genetic correlations among psychiatric and immune-related phenotypes based on genome-wide association data.
Am J Med Genet B Neuropsychiatr Genet
. 2018;177(7):641–57.
38.
Benros ME, Mortensen PB, Eaton WW. Autoimmune diseases and infections as risk factors for schizophrenia.
Ann N Y Acad Sci
. 2012;1262:56–66.
39.
Checa-Ros A, Jeréz-Calero A, Molina-Carballo A, Campoy C, Muñoz-Hoyos A. Current evidence on the role of the gut microbiome in ADHD pathophysiology and therapeutic implications.
Nutrients
. 2021;13(1):249.
40.
Aarts E, Ederveen THA, Naaijen J, Zwiers MP, Boekhorst J, Timmerman HM, et al. Gut microbiome in ADHD and its relation to neural reward anticipation.
PLoS One
. 2017;12(9):e0183509.
41.
Scheres A, Milham MP, Knutson B, Castellanos FX. Ventral striatal hyporesponsiveness during reward anticipation in attention-deficit/hyperactivity disorder.
Biol Psychiatry
. 2007;61(5):720–4.
42.
Wan L, Ge WR, Zhang S, Sun YL, Wang B, Yang G. Case-Control Study of the effects of gut microbiota composition on neurotransmitter metabolic pathways in children with attention deficit hyperactivity disorder.
Front Neurosci
. 2020;14:127.
43.
Singhal M, Turturice BA, Manzella CR, Ranjan R, Metwally AA, Theorell J, et al. Serotonin transporter deficiency is associated with dysbiosis and changes in metabolic function of the mouse intestinal microbiome.
Sci Rep
. 2019;9(1):2138.
44.
Quagliariello A, Del Chierico F, Russo A, Reddel S, Conte G, Lopetuso LR, et al. Gut microbiota profiling and gut-brain crosstalk in children affected by pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections.
Front Microbiol
. 2018;9:675.
45.
Bercik P, Denou E, Collins J, Jackson W, Lu J, Jury J, et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice.
Gastroenterology
. 2011;141(2):599e1–6093.
46.
Tsai SJ. Role of neurotrophic factors in attention deficit hyperactivity disorder.
Cytokine Growth Factor Rev
. 2017;34:35–41.
47.
Cheng S-W, Chan H-Y. Antipsychotic prescription pattern among child and adolescent patients with psychiatric illnesses in Taiwan.
Taiwan J Psychiatry
. 2017;31:222–31.
© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.